Author + information
- Received May 9, 2007
- Revision received June 27, 2007
- Accepted July 7, 2007
- Published online October 16, 2007.
- Dean J. Kereiakes, MD, FACC⁎,⁎ (, )
- Paul S. Teirstein, MD, FACC†,
- Ian J. Sarembock, MB, ChB, MD‡,
- David R. Holmes Jr, MD§,
- Mitchell W. Krucoff, MD, FACC¶,
- William W. O’Neill, MD∥,
- Ron Waksman, MD, FACC#,
- David O. Williams, MD⁎⁎,
- Jeffrey J. Popma, MD, FACC††,
- Maurice Buchbinder, MD, FACC†,
- Roxana Mehran, MD††,
- Ian T. Meredith, MBBS, PhD, FACC‡‡,
- Jeffrey W. Moses, MD, FACC†† and
- Gregg W. Stone, MD, FACC††
- ↵⁎Reprint requests and correspondence:
Dr. Dean J. Kereiakes, Lindner Research Center, 2123 Auburn Avenue, Suite 424, Cincinnati, Ohio 45219.
Percutaneous coronary intervention (PCI) has played an integral role in the therapeutic management strategies for patients who present with either acute coronary syndromes or stable angina pectoris. The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial enrolled patients with chronic stable angina and at least 1 significant (≥70%) angiographic coronary stenosis who were randomly assigned to an initial treatment of either PCI in conjunction with optimal medical therapy or optimal medical therapy alone. Although the initial management strategy of PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events, improvement in angina-free status and a reduction in the requirement for subsequent revascularization was observed. An in-depth analysis of the COURAGE trial design and execution is provided.
- Received May 9, 2007.
- Revision received June 27, 2007.
- Accepted July 7, 2007.
- American College of Cardiology Foundation